Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes

Hospital practice (1995)

Volumn 42, Issue 3, 2014, Pages 96-108

  Brunton, Stephen ^a   Reid, Timothy S ^a  

^a Primary Care Metabolic Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; GLUCOSE BLOOD LEVEL; GLUCOSIDE; LIPID; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY; METABOLISM; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOLOGY;

BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; LIPIDS; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84925224939     PISSN: 21548331     EISSN: None     Source Type: Journal    
DOI: 10.3810/hp.2014.08.1122     Document Type: Review

References (0)